NO313405B1 - Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS - Google Patents

Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS Download PDF

Info

Publication number: NO313405B1
Authority: NO; Norway
Prior art keywords: ards; treatment; irds; composition; surfactant
Prior art date: 1994-09-28

Application number

NO19971403A

Other languages

English (en)

Norwegian (no)

Other versions

NO971403D0 (no

NO971403L (no

Inventor

Dietrich Haefner

Paul-Georg Germann

Klaus Eistetter

Ulrich Kilian

Original Assignee

Takeda Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-09-28

Filing date

1997-03-25

Publication date

2002-09-30

1997-03-25 Application filed by Takeda Gmbh filed Critical Takeda Gmbh

1997-03-25 Publication of NO971403D0 publication Critical patent/NO971403D0/no

1997-04-17 Publication of NO971403L publication Critical patent/NO971403L/no

2002-09-30 Publication of NO313405B1 publication Critical patent/NO313405B1/no

Links

239000000203 mixture Substances 0.000 title claims abstract description 26
206010001052 Acute respiratory distress syndrome Diseases 0.000 title claims abstract description 20
239000003580 lung surfactant Substances 0.000 title claims abstract description 16
201000000028 adult respiratory distress syndrome Diseases 0.000 title claims abstract description 15
239000003862 glucocorticoid Substances 0.000 title claims abstract description 8
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 14
210000004072 lung Anatomy 0.000 claims description 7
229940066294 lung surfactant Drugs 0.000 claims description 7
150000003904 phospholipids Chemical class 0.000 claims description 6
239000004094 surface-active agent Substances 0.000 claims description 6
102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 claims description 5
108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 claims description 5
229960002537 betamethasone Drugs 0.000 claims description 5
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 5
208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims description 4
206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims description 4
201000002652 newborn respiratory distress syndrome Diseases 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 3
229960003728 ciclesonide Drugs 0.000 claims description 3
229960003957 dexamethasone Drugs 0.000 claims description 3
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 claims description 2
108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
229940079593 drug Drugs 0.000 claims 1
150000002632 lipids Chemical class 0.000 claims 1
229960001810 meprednisone Drugs 0.000 claims 1
PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims 1
208000011580 syndromic disease Diseases 0.000 abstract description 2
244000144985 peep Species 0.000 description 9
241001465754 Metazoa Species 0.000 description 5
230000009467 reduction Effects 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
229960004436 budesonide Drugs 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000007789 gas Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229960004584 methylprednisolone Drugs 0.000 description 2
239000000843 powder Substances 0.000 description 2
229940063649 survanta Drugs 0.000 description 2
241000283690 Bos taurus Species 0.000 description 1
241000700159 Rattus Species 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229940092456 curosurf Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000036732 histological change Effects 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
210000004276 hyalin Anatomy 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000003622 mature neutrocyte Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000009423 ventilation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Cell Biology (AREA)
Immunology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Marine Sciences & Fisheries (AREA)
Gastroenterology & Hepatology (AREA)
Developmental Biology & Embryology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physiology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Processes Of Treating Macromolecular Substances (AREA)
Compositions Of Macromolecular Compounds (AREA)
Steroid Compounds (AREA)

NO19971403A 1994-09-28 1997-03-25 Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS NO313405B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE4434629A DE4434629C1 (de)	1994-09-28	1994-09-28	Zusammensetzungen zur Behandlung von IRDS und ARDS
PCT/EP1995/003816 WO1996009831A2 (fr)	1994-09-28	1995-09-27	Compositions contenant au moins un glucocorticoide en association avec un surfactant pulmonaire pour le traitement du syndrome de detresse respiratoire du nourrisson et des insuffisances respiratoires aigues

Publications (3)

Publication Number	Publication Date
NO971403D0 NO971403D0 (no)	1997-03-25
NO971403L NO971403L (no)	1997-04-17
NO313405B1 true NO313405B1 (no)	2002-09-30

Family

ID=6529394

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19971403A NO313405B1 (no)	1994-09-28	1997-03-25	Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS

Country Status (25)

Country	Link
US (1)	US5891844A (fr)
EP (1)	EP0783314B1 (fr)
JP (1)	JP4425991B2 (fr)
KR (1)	KR100365030B1 (fr)
CN (1)	CN1100542C (fr)
AT (1)	ATE241372T1 (fr)
AU (1)	AU705099B2 (fr)
BG (1)	BG62556B1 (fr)
CA (1)	CA2201377C (fr)
CZ (1)	CZ292846B6 (fr)
DE (2)	DE4434629C1 (fr)
DK (1)	DK0783314T3 (fr)
EE (1)	EE03422B1 (fr)
ES (1)	ES2201120T3 (fr)
FI (1)	FI118886B (fr)
HU (1)	HU226958B1 (fr)
MX (1)	MX9702303A (fr)
NO (1)	NO313405B1 (fr)
NZ (1)	NZ294587A (fr)
PL (1)	PL187496B1 (fr)
PT (1)	PT783314E (fr)
RU (1)	RU2157222C2 (fr)
SK (1)	SK284446B6 (fr)
UA (1)	UA43378C2 (fr)
WO (1)	WO1996009831A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6039932A (en) *	1996-09-27	2000-03-21	3M Innovative Properties Company	Medicinal inhalation aerosol formulations containing budesonide
DE69835594T2 (de) *	1997-02-17	2007-08-16	Altana Pharma Ag	Zusammensetzungen zur behandlung von irds oder ards die 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten
US20060281681A1 (en)	1997-05-28	2006-12-14	Pilon Aprile L	Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US7122344B2 (en)	1997-05-28	2006-10-17	Claragen, Inc.	Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US6946117B1 (en)	1997-09-29	2005-09-20	Nektar Therapeutics	Stabilized preparations for use in nebulizers
US20020017295A1 (en) *	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en)	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US6433040B1 (en) *	1997-09-29	2002-08-13	Inhale Therapeutic Systems, Inc.	Stabilized bioactive preparations and methods of use
CN1194833A (zh) *	1997-10-08	1998-10-07	刘柏宏	肺活素
US6858223B2 (en)	1998-06-23	2005-02-22	Altana Pharma Ag	Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS)
JP2003501481A (ja) *	1999-06-11	2003-01-14	ビイクグルデンロンベルクヒエーミツシエフアブリークゲゼルシヤフトミツトベシユレンクテルハフツング	サーファクタントタンパク質ｂ（ｓｐ−ｂ）改変体およびサーファクタントタンパク質ｃ（ｓｐ−ｃ）改変体を含有する医薬品製剤
AU6083899A (en)	1999-09-16	2001-04-17	Aventis Behring Gmbh	Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
DE19957898A1 (de) *	1999-12-01	2001-06-07	Byk Gulden Lomberg Chem Fab	Neue Verwendung von Lungensurfactant
DE10018022A1 (de) *	2000-04-12	2001-10-31	Byk Gulden Lomberg Chem Fab	Neue Verwendung von Lungensurfactant zur Prophylaxe oder Frühbehandlung von akuten Lungenerkrankungen
US20040254112A1 (en) *	2000-04-12	2004-12-16	Dietrich Hafner	Use of pulmonary surfactant for the early treatment of acute pulmonary diseases
AU2001265876A1 (en) *	2000-04-12	2001-10-23	Byk Gulden Lomberg Chemische Fabrik G.M.B.H.	Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
US8404217B2 (en)	2000-05-10	2013-03-26	Novartis Ag	Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7442388B2 (en) *	2000-05-10	2008-10-28	Weers Jeffry G	Phospholipid-based powders for drug delivery
RU2191031C2 (ru) *	2001-01-10	2002-10-20	Московский НИИ педиатрии и детской хирургии	Способ лечения пневмоний у глубоконедоношенных детей, находящихся на искусственной вентиляции легких
DE10132307A1 (de) *	2001-07-06	2003-01-30	Aventis Behring Gmbh	Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
US20030099601A1 (en) *	2001-11-27	2003-05-29	Gordon Marc S.	Inhalation lung surfactant therapy
US6998384B2 (en) *	2001-12-12	2006-02-14	The Penn State Research Foundation	Surfactant prevention of lung complications from cancer chemotherapy
US7368102B2 (en)	2001-12-19	2008-05-06	Nektar Therapeutics	Pulmonary delivery of aminoglycosides
US20040023935A1 (en) *	2002-08-02	2004-02-05	Dey, L.P.	Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) *	2002-12-06	2004-06-10	Dey, L.P.	Stabilized albuterol compositions and method of preparation thereof
WO2004110450A1 (fr)	2003-06-16	2004-12-23	Altana Pharma Ag	Composition comprenant un surfactant pulmonaire et un inhibiteur des pde5 pour le traitement de maladies pulmonaires
US8371292B2 (en) *	2003-09-16	2013-02-12	Nycomed Gmbh	Use of ciclesonide for the treatment of respiratory diseases
US7582312B2 (en)	2004-11-15	2009-09-01	Discovery Laboratories, Inc.	Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) *	2004-12-10	2008-12-09	L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude	Simplified process simulator
EP2298349A1 (fr)	2005-01-06	2011-03-23	Discovery Laboratories, Inc.	Schéma de traitment utilisant un surfactant pour la prévention ou traitment de la dysplasie boncho-pulmonaire
KR100891595B1 (ko) *	2005-02-28	2009-04-03	주식회사 케이티앤지	혈액 단백질의 삼출을 감소시키는 조성물
WO2008036293A1 (fr) *	2006-09-19	2008-03-27	Discovery Laboratories, Inc.	Formulations de surfactant pulmonaire et procédés favorisant l'élimination du mucus
EP2022798A1 (fr) *	2007-08-09	2009-02-11	CHIESI FARMACEUTICI S.p.A.	Peptides synthétiques de surfactant pulmonaire
WO2012077127A1 (fr) *	2010-12-10	2012-06-14	Indian Institute Of Technology, Bombay	Composition de tensioactif dépourvue de protéines destinée à des pneumopathies et son procédé de préparation
WO2013188016A2 (fr)	2012-05-04	2013-12-19	Discovery Laboratories, Inc.	Thérapie utilisant des surfactants pour exposition à un rayonnement ionisant
CN106310280A (zh) *	2016-08-18	2017-01-11	滨州医学院	地瑞那韦增强糖皮质激素抗炎作用的医药新用途
BR112019012922A2 (pt) *	2016-12-22	2019-12-10	Chiesi Farm Spa	combinação de um surfactante pulmonar, uso de uma combinação de um surfactante pulmonar e kit
JP7378425B2 (ja)	2018-04-23	2023-11-13	シエシーファルマセウティチィソシエタペルアチオニ	肺サーファクタントおよびｂｐｄの予防のためのステロイドを含む治療的組合せ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1988000868A1 (fr) *	1986-08-08	1988-02-11	Kurzinski Cass R	Appareil et procede permettant de couler en continu des brames d'acier
US4944941A (en) *	1987-08-07	1990-07-31	Genentech, Inc.	Methods and compositions for the treatment of lung conditions
RU2039560C1 (ru) *	1988-04-18	1995-07-20	Центр по химии лекарственных средств ВНИИХФИ	Вещество, обладающее противоопухолевой активностью
US5006343A (en) *	1988-12-29	1991-04-09	Benson Bradley J	Pulmonary administration of pharmaceutically active substances

1994
- 1994-09-28 DE DE4434629A patent/DE4434629C1/de not_active Expired - Lifetime
1995
- 1995-09-27 AT AT95935387T patent/ATE241372T1/de active
- 1995-09-27 CZ CZ1997940A patent/CZ292846B6/cs not_active IP Right Cessation
- 1995-09-27 HU HU9801664A patent/HU226958B1/hu not_active IP Right Cessation
- 1995-09-27 WO PCT/EP1995/003816 patent/WO1996009831A2/fr not_active Ceased
- 1995-09-27 MX MX9702303A patent/MX9702303A/es unknown
- 1995-09-27 RU RU97106790/14A patent/RU2157222C2/ru not_active IP Right Cessation
- 1995-09-27 UA UA97042034A patent/UA43378C2/uk unknown
- 1995-09-27 CN CN95196265A patent/CN1100542C/zh not_active Expired - Fee Related
- 1995-09-27 ES ES95935387T patent/ES2201120T3/es not_active Expired - Lifetime
- 1995-09-27 CA CA002201377A patent/CA2201377C/fr not_active Expired - Fee Related
- 1995-09-27 EP EP95935387A patent/EP0783314B1/fr not_active Expired - Lifetime
- 1995-09-27 JP JP51137796A patent/JP4425991B2/ja not_active Expired - Fee Related
- 1995-09-27 AU AU37428/95A patent/AU705099B2/en not_active Ceased
- 1995-09-27 EE EE9700084A patent/EE03422B1/xx unknown
- 1995-09-27 SK SK401-97A patent/SK284446B6/sk not_active IP Right Cessation
- 1995-09-27 DK DK95935387T patent/DK0783314T3/da active
- 1995-09-27 PL PL95319608A patent/PL187496B1/pl not_active IP Right Cessation
- 1995-09-27 PT PT95935387T patent/PT783314E/pt unknown
- 1995-09-27 KR KR1019970701971A patent/KR100365030B1/ko not_active Expired - Fee Related
- 1995-09-27 DE DE59510705T patent/DE59510705D1/de not_active Expired - Lifetime
- 1995-09-27 NZ NZ294587A patent/NZ294587A/en not_active IP Right Cessation
1997
- 1997-03-25 NO NO19971403A patent/NO313405B1/no not_active IP Right Cessation
- 1997-03-26 FI FI971277A patent/FI118886B/fi not_active IP Right Cessation
- 1997-04-25 BG BG101441A patent/BG62556B1/bg unknown
- 1997-06-19 US US08/809,687 patent/US5891844A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
FI971277L (fi)	1997-05-27
ATE241372T1 (de)	2003-06-15
DE59510705D1 (de)	2003-07-03
SK40197A3 (en)	1998-02-04
PL319608A1 (en)	1997-08-18
JP4425991B2 (ja)	2010-03-03
US5891844A (en)	1999-04-06
WO1996009831A2 (fr)	1996-04-04
EE9700084A (et)	1997-10-15
JPH10506119A (ja)	1998-06-16
CZ94097A3 (en)	1997-09-17
EP0783314B1 (fr)	2003-05-28
HU226958B1 (en)	2010-03-29
EE03422B1 (et)	2001-06-15
DE4434629C1 (de)	1996-06-27
PT783314E (pt)	2003-10-31
BG62556B1 (bg)	2000-02-29
CZ292846B6 (cs)	2003-12-17
EP0783314A2 (fr)	1997-07-16
BG101441A (en)	1997-09-30
CN1100542C (zh)	2003-02-05
WO1996009831A3 (fr)	1996-05-23
CA2201377A1 (fr)	1996-04-04
AU705099B2 (en)	1999-05-13
NZ294587A (en)	1998-07-28
NO971403D0 (no)	1997-03-25
FI118886B (fi)	2008-04-30
ES2201120T3 (es)	2004-03-16
AU3742895A (en)	1996-04-19
PL187496B1 (pl)	2004-07-30
MX9702303A (es)	1997-06-28
SK284446B6 (sk)	2005-04-01
HK1003869A1 (en)	1998-11-13
KR100365030B1 (ko)	2003-03-10
RU2157222C2 (ru)	2000-10-10
NO971403L (no)	1997-04-17
CA2201377C (fr)	2008-07-29
CN1163571A (zh)	1997-10-29
DK0783314T3 (da)	2003-12-01
FI971277A0 (fi)	1997-03-26
KR970706006A (ko)	1997-11-03
UA43378C2 (uk)	2001-12-17
HUT77931A (hu)	1998-11-30

Legal Events

Date	Code	Title	Description
2013-03-25	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: TAKEDA GMBH, DE
2015-04-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US5891844A (en)	1999-04-06	Compositions for treating IRDS and ARDS with a combination of a Glucocorticosteroid and a lung surfactant, and their use
MXPA97002303A (en)	1997-06-01	Compositions containing at least one glucocorticoid in combination with a pulmonary surgical agent for the treatment of child respiratory suffering syndrome and respiratory suffering syndrome ag
JP5666569B2 (ja)	2015-02-12	サーファクタントタンパク質ｂ（ｓｐ−ｂ）およびサーファクタントタンパク質ｃ（ｓｐ−ｃ）の類似体を含有する改善された再構築サーファクタント組成物
KR20150089006A (ko)	2015-08-04	재구성된 폐 계면활성제
JP2023113852A (ja)	2023-08-16	進行性のｂｐｄの処置のための肺サーファクタント及びステロイドを含む処置的組み合わせ物
WO2001019392A1 (fr)	2001-03-22	Combinaison de c1-inh et d'un agent tensioactif pulmonaire pour le traitement des troubles respiratoires
KR100191381B1 (ko)	1999-06-15	스테로이드 요법에 의한 부작용을 경감 또는 예방하고 코르티코스테로이드 요법을 안전화시키기 위한 조성물
DE69928279T2 (de)	2006-08-17	Lungensurfactant zubereitungen enthaltendes behandlungset
EP1480667B1 (fr)	2006-12-06	Compositions contenant des tensioactifs pulmonaires et une polymyxine aux proprietes de surface ameliorees
EP1435994B1 (fr)	2010-05-19	Nouvelle utilisation de surfactant pulmonaire
HK1003869B (en)	2003-10-31	Compositions containing at least one glucocorticoid in combination with a pulmon ary surfactant for the treatment of irds and ards
JPH06165655A (ja)	1994-06-14	コレステロール低減用組成物
Spragg et al.	1998	Surfactant Replacement in Patients with Ards: Results of Clinical Trials
Golembeski et al.	1990	New strategies for prevention of neonatal respiratory distress syndrome: Acceleration of fetal lung maturation and exogenous surfactant replacement
Erçin et al.	2016	New Generation Surfactants, Are They A Hope For Better Outcomes?